Literature DB >> 7065521

Theophylline serum concentration and therapeutic effect in severe acute bronchial obstruction: the optimal use of intravenously administered aminophylline.

S Vozeh, G Kewitz, A Perruchoud, M Tschan, C Kopp, M Heitz, F Follath.   

Abstract

In 20 patients with acute exacerbation of bronchial obstruction, the therapeutic effect of high (20 mg/L) and low (10 mg/L) serum concentrations of theophylline was compared in a double-blind randomized study. The theophylline dose, administered as a continuous aminophylline infusion, was individually adjusted by means of repeated measurements of serum concentrations. At 28 h after starting therapy the high concentration group showed a significantly greater improvement in pulmonary function as assessed by FEV1 (0.57 +/- 0.52 L (mean +/- SD) versus 0.1 +/- 0.18 L, p less than 0.01) and FVC (1.0 +/- 0.65 L versus 0.01 +/- 0.66 L, p less than 0.02). As a measure of the overall clinical improvement, the time during which intravenous therapy was required was also shorter in the high-dose group (61.7 +/- 25.8 h (mean +/- SD) versus 116 +/- 49.7 h, p less than 0.02). The occurrence of side effects in the two groups was not significantly different. In patients with severe acute bronchial obstruction, serum theophylline concentrations around 20 mg/L seemed to offer a definite therapeutic advantage, thus, routine serum concentration measurements and the use of accurate infusion devices for optimal dose adjustment may be justified.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7065521     DOI: 10.1164/arrd.1982.125.2.181

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  26 in total

Review 1.  Concentration-controlled or effect-controlled trials: useful alternatives to conventional dose-controlled trials?

Authors:  A Grahnén; M O Karlsson
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  Randomized exposure-controlled trials; impact of randomization and analysis strategies.

Authors:  Kristin E Karlsson; Anders Grahnén; Mats O Karlsson; E Niclas Jonsson
Journal:  Br J Clin Pharmacol       Date:  2007-04-10       Impact factor: 4.335

Review 3.  Therapeutic drug monitoring and patient outcome. A review of the issues.

Authors:  A L Tonkin; F Bochner
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

4.  Xanthines in respiratory diseases.

Authors:  J A Mazza
Journal:  Can Fam Physician       Date:  1982-10       Impact factor: 3.275

Review 5.  Cost-effectiveness of therapeutic drug monitoring.

Authors:  S Vozeh
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes?

Authors:  M H Ensom; G A Davis; C D Cropp; R J Ensom
Journal:  Clin Pharmacokinet       Date:  1998-04       Impact factor: 6.447

7.  Rapid prediction of individual dosage requirements for lignocaine.

Authors:  S Vozeh; M Berger; M Wenk; R Ritz; F Follath
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

Review 8.  A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products.

Authors:  L Hendeles; R P Iafrate; M Weinberger
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

Review 9.  The effect of respiratory disorders on clinical pharmacokinetic variables.

Authors:  A M Taburet; C Tollier; C Richard
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

10.  Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials.

Authors:  R Graham Barr; Brian H Rowe; Carlos A Camargo
Journal:  BMJ       Date:  2003-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.